Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) will announce its Q4 and full year 2020 financial results on March 4, 2021, prior to U.S. market opening. A conference call and webcast will follow at 8:00 a.m. ET to discuss the results and company updates. Fulcrum is advancing its proprietary product engine aimed at treating genetically defined rare diseases, with notable developments including losmapimod in Phase 2 for FSHD and Phase 3 for COVID-19, alongside FTX-6058 in Phase 1 for sickle cell disease.

Positive

• Advancements in losmapimod to Phase 2 for facioscapulohumeral muscular dystrophy
• Advancements in losmapimod to Phase 3 for COVID-19
• FTX-6058 in Phase 1 for treating sickle cell disease and beta thalassemia

Negative

• None.

CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2020 financial results will be released on Thursday, March 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 6376419

Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 6376419

An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Please visit www.fulcrumtx.com.

Contact:
Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com

FAQ

When will Fulcrum Therapeutics release its Q4 2020 financial results?

Fulcrum Therapeutics will release its Q4 2020 financial results on March 4, 2021, before the U.S. financial markets open.

What time is the conference call for Fulcrum's financial results?

The conference call to discuss Fulcrum's financial results will take place at 8:00 a.m. ET on March 4, 2021.

What are the key clinical developments announced by Fulcrum Therapeutics?

Fulcrum is advancing losmapimod to Phase 2 for FSHD and Phase 3 for COVID-19, and FTX-6058 is in Phase 1 for sickle cell disease.